Serum Progranulin Levels as Markers of Mammary Tumors in Women

https://doi.org/10.33860/jbc.v6i1.3445

Authors

  • Rosa Dwi Wahyuni Departement of clinical pathology, Faculty of Medicine, Universitas Tadulako, Palu, Indonesia
  • Rahma Departement of Pediatric Health, Faculty of Medicine, Universitas Tadulako, Palu, Indonesia
  • Dachruddin Ngatimin Departement Opthalmology, Faculty of Medicine, Universitas Tadulako, Palu, Indonesia
  • M. Sabir Department of Microbiology, Faculty of Medicine, Universitas Tadulako, Palu, Indonesia
  • Abd. Farid Lewa Department of Nutrition, Poltekkes Kemenkes Palu, Palu, Indonesia

Keywords:

Serum Progranulin , Mammary

Abstract

Introduction: Carcinoma mammae is a malignant tumor that develops from breast cells and has the potential to invade the surrounding tissue (invasive) or metastasize to other parts of the body. While it is more frequently diagnosed in women, there are cases where it is also found in males. Purpose: This study aims to identify variations in serum progranulin levels as distinguishing factors between benign mammary tumors and mammary carcinoma. Method: The research adopts a quantitative approach with a cross-sectional design to ascertain the significance of serum progranulin levels in patients with mammary tumors. The study includes the entire accessible population diagnosed with mammary tumors by clinicians in the Surgical Oncology Department of Dr. Wahidin Sudirohusodo Teaching Hospital in Makassar, with a sample size of 78 individuals. Normality is assessed using the Kruskal-Wallis test, and differences are examined through the Mann-Whitney test. Result: A substantial difference exists in serum progranulin levels among breast carcinoma patients with benign mammary tumors and the control group (P<0.001). The mean difference in benign tumors is 121.08±56.84, whereas in breast carcinoma, it is 239.54±34.79. Conclusion: Serum progranulin levels can be employed as a potential alternative for diagnostic support in the early detection of both benign mammary tumors and mammary carcinoma.

Downloads

Download data is not yet available.

Author Biography

Dachruddin Ngatimin, Departement Opthalmology, Faculty of Medicine, Universitas Tadulako, Palu, Indonesia

Anuntaloko Hospital, Parigi Moutong, Central Sulawesi

References

American Cancer Society. (2016). Breast Cancer Early Detection and Diagnosis American Cancer Society Recommendations for the Early Detection of Breast Cancer. American Cancer Society, 1–55. Retrieved from https://www.cancer.org/content/dam/CRC/PDF/Public/8579.00.pdf

Anindita, S., Marnolia, A., Putra, H. H., Haikal, M. C., & Tambunan, U. S. F. (2018). Novel inhibitors of T315I mutant BCR-ABL1 tyrosine kinase for chronic myeloid leukemia disease through fragment-based drug design. In Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics). Springer International Publishing. https://doi.org/10.1007/978-3-319-94968-0_17

Galimberti, D., Fumagalli, G. G., Fenoglio, C., Cioffi, S. M. G., Arighi, A., Serpente, M., … Scarpini, E. (2018). Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. Neurobiology of Aging, 62, 245.e9-245.e12. https://doi.org/10.1016/j.neurobiolaging.2017.10.016

Jian, J., Konopka, J., & Liu, C. (2013). Insights into the role of progranulin in immunity, infection, and inflammation. Journal of Leukocyte Biology, 93(2), 199–208. https://doi.org/10.1189/jlb.0812429

Kamińska, M., Ciszewski, T., Łopacka-Szatan, K., Miotła, P., & Starosławska, E. (2015). Breast cancer risk factors. Przeglad Menopauzalny, 14(3), 196–202. https://doi.org/10.5114/pm.2015.54346

KEMENKES. (2018). Riset Kesehatan Dasar (RISKESDAS) 2018.

Leerkes, M. R., Caballero, O. L., Mackay, A., Torloni, H., O’Hare, M. J., Simpson, A. J. G., & De Souza, S. J. (2002). In silico comparison of the transcriptome derived from purified normal breast cells and breast tumor cell lines reveals candidate upregulated genes in breast tumor cells. Genomics, 79(2), 257–265. https://doi.org/10.1006/geno.2002.6691

Lu, R., & Serrero, G. (2001). Mediation of estrogen mitogenic effect in human breast cancer MCF-7 cells by PC-cell-derived growth factor (PCDGF/granulin precursor). Proceedings of the National Academy of Sciences of the United States of America, 98(1), 142–147. https://doi.org/10.1073/pnas.98.1.142

Martens, L. H., Zhang, J., Barmada, S. J., Zhou, P., Kamiya, S., Sun, B., … Farese, R. V. (2012). Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury. Journal of Clinical Investigation, 122(11), 3955–3959. https://doi.org/10.1172/JCI63113

McTiernan, A. (2003). Behavioral Risk Factors in Breast Cancer: Can Risk Be Modified? The Oncologist, 8(4), 326–334. https://doi.org/10.1634/theoncologist.8-4-326

Momenimovahed, Z., & Salehiniya, H. (2019). Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer: Targets and Therapy, 11, 151–164. https://doi.org/10.2147/BCTT.S176070

Olawoye, O. S., Adeagbo, B. A., & Bolaji, O. O. (2018). Moringa oleifera leaf powder alters the pharmacokinetics of amodiaquine in healthy human volunteers. Journal of Clinical Pharmacy and Therapeutics, 43(5), 626–632. https://doi.org/10.1111/jcpt.12725

Ong, C. H. P., & Bateman, A. (2003). Progranulin (granulin-epithelin precursor, PC-cell derived growth factor, acrogranin) in proliferation and tumorigenesis. Histology and Histopathology, 18(4), 1275–1288. https://doi.org/10.14670/HH-18.1275

Smith, R. A., Manassaram-Baptiste, D., Brooks, D., Cokkinides, V., Doroshenk, M., Saslow, D., … Brawley, O. W. (2014). Cancer screening in the United States, 2014: A review of current American Cancer Society guidelines and current issues in cancer screening. CA: A Cancer Journal for Clinicians, 64(1), 30–51. https://doi.org/10.3322/caac.21212

Sukmayenti, S., & Sari, N. (2019). Analisis Determinan Kanker Payudara Pada Wanitadi Rsup Dr. M.Djamil Padang Tahun 2018. Jurnal Kesehatan, 7621(1), 77–86. https://doi.org/10.23917/jk.v0i1.7668

Sun, Y. S., Zhao, Z., Yang, Z. N., Xu, F., Lu, H. J., Zhu, Z. Y., … Zhu, H. P. (2017). Risk factors and preventions of breast cancer. International Journal of Biological Sciences, 13(11), 1387–1397. https://doi.org/10.7150/ijbs.21635

Tangkeangsirisin, W., & Serrero, G. (2004). PC cell-derived growth factor (PCDGF/GP88, progranulin) stimulates migration, invasiveness and VEGF expression in breast cancer cells. Carcinogenesis, 25(9), 1587–1592. https://doi.org/10.1093/carcin/bgh171

Tkaczuk, K. R., Yue, B., Zhan, M., Tait, N., Yarlagadda, L., Dai, H., & Serrero, G. (2011). Increased circulating level of the survival factor GP88 (Progranulin) in the serum of breast cancer patients when compared to healthy subjects. Breast Cancer: Basic and Clinical Research, 5(1), 155–162. https://doi.org/10.4137/BCBCR.S7224

Wahyunie S, Uleng B, Ibrahim AS, Ilhamjaya P, William H, M. A. (2015). Serum Progranulin Analysis in Carcinoma Patients Mammae. In Tesis. Makassar: Unhas.

Winters, S., Martin, C., Murphy, D., & Shokar, N. K. (2017). Breast Cancer Epidemiology, Prevention, and Screening. In Progress in Molecular Biology and Translational Science (Vol. 151). Elsevier Inc. https://doi.org/10.1016/bs.pmbts.2017.07.002

Downloads

Published

2024-03-31

How to Cite

Wahyuni, R. D., Rahma, R., Ngatimin, D., M. Sabir, M. S., & Lewa, A. F. (2024). Serum Progranulin Levels as Markers of Mammary Tumors in Women. Jurnal Bidan Cerdas, 6(1), 11–18. https://doi.org/10.33860/jbc.v6i1.3445

Issue

Vol. 6 No. 1 (2024)

Section

Articles

License

Copyright (c) 2024 Rosa Dwi Wahyuni, Rahma, Dachruddin Ngatimin, M. Sabir, Abd. Farid Lewa

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Authors who publish with Jurnal Bidan Cerdas agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.

Creative Commons License
This work is licensed under a Creative Commons Attribution-Share Alike 4.0 International License

You are free to:

  • Adapt, remix, transform, and build upon the material for any purpose, even commercially.
  • The licensor cannot revoke these freedoms as long as you follow the license terms.